Fetuin-A and incident diabetes mellitus in older persons

JAMA

Volumn 300, Issue 2, 2008, Pages 182-188

  Ix, Joachim H ^a,b   Wassel, Christina L ^c,d   Kanaya, Alka M ^d   Vittinghoff, Eric ^d   Johnson, Karen C ^e   Koster, Annemarie ^f   Cauley, Jane A ^g   Harris, Tamara B ^f   Cummings, Steven R ^d,h   Shlipak, Michael G ^d,i  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

ⁱ SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FETUIN A; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; AGED; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENTAL FINDING; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MODEL; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 47049126504     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.2.182     Document Type: Article

References (46)

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288(14):1723-1727.
2. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195-1200.
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414-1431.
4. Howard BV, Rodriguez BL, Bennett PH, et al. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology. Circulation. 2002;105(18):e132-e137.
5. Perseghin G, Ghosh S, Gerow K, et al. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes. 1997;46(6):1001-1009.
6. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316(5829):1331-1336.
7. McNeely MJ, Boyko EJ, Weigle DS, et al. Association between baseline plasma leptin levels and subsequent development of diabetes in Japanese Americans. Diabetes Care. 1999;22(1):65-70.
8. Festa A, D'Agostino R Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131-1137.
9. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360(9326):57-58.
10. Ix JH, Chertow GM, Shlipak MG, et al. Fetuin-A and kidney function in persons with coronary artery disease: data from the Heart and Soul Study. Nephrol Dial Transplant. 2006;21(8):2144-2151.
11. Rauth G, Poschke O, Fink E, et al. The nucleotide and partial amino acid sequences of rat fetuin: identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem. 1992;204(2):523-529.
12. Auberger P, Falquerho L, Contreres JO, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell. 1989;58(4):631-640.
13. Mathews ST, Singh GP, Ranalletta M, et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes. 2002;51(8):2450-2458.
14. Mathews ST, Rakhade S, Zhou X, et al. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun. 2006;350(2):437-443.
15. Stefan N, Hennige AM, Staiger H, et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. 2006;29(4):853-857.
16. Mori K, Emoto M, Yokoyama H, et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects [letter]. Diabetes Care. 2006;29(2):468.
17. Ix JH, Shlipak MG, Brandenburg VM, et al. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113(14):1760-1767.
18. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73:1-11. doi:10.1093/biomet/ 73.1.1.
19. Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibodybased enzyme-linked immunosorbent assay. Blood. 1988;71(1):220-225.
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
21. Barlow WE, Ichikawa L, Rosner D, et al. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12):1165-1172.
22. Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal. 1999;5(2):99-112.
23. Lin DYWL. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
24. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the Evidence Report: National Institutes of Health. Obes Res. 1998;6(suppl 2):51S-209S.
25. Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993;7(11):1445-1455.
26. Mathews ST, Srinivas PR, Leon MA, et al. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci. 1997;61(16):1583-1592.
27. Grunberger GMS, Mathews ST, Deutsch DD. Tyrosine kinase inhibitors. In: Grunberger GMS, Zick Y, eds. Insulin Signaling: From Cultured Cells to Animal Models, Frontiers in Animal Diabetes Research. New York, NY: CRC Press; 2002:281-298.
28. Cintrón VJ, Ko MS, Chi KD, et al. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res. 2001;1(4):249-263.
29. Vionnet N, Hani EH, Dupont S, et al. Genome-wide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet. 2000;67(6):1470-1480.
30. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A. 2000;97(26):14478-14483.
31. Cayatte AJ, Kumbla L, Subbiah MT. Marked acceleration of exogenous fatty acid incorporation into cellular triglycerides by fetuin. J Biol Chem. 1990;265(10):5883-5888.
32. Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein /fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112(3):357-366.
33. Westenfeld R, Schafer C, Smeets R, et al. Fetuin-A (Ahsg) prevents extraosseous calcification induced by uraemia and phosphate challenge in mice. Nephrol Dial Transplant. 2007;22(6):1537-1546.
34. Ix JH, Chertow GM, Shlipak MG, et al. Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the Heart and Soul Study. Circulation. 2007;115(19):2533-2539.
35. Kaden JJ, Reinohl JO, Blesch B, et al. Systemic and local levels of fetuin-A in calcific aortic valve stenosis. Int J Mol Med. 2007;20(2):193-197.
36. Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005;67(6):2295-2304.
37. Wang AY, Woo J, Lam CW, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant. 2005;20(8):1676-1685.
38. Lim P, Collet JP, Moutereau S, et al. Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. Clin Chem. 2007;53(10):1835-1840.
39. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int. 2005;67(6):2383-2392.
40. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (Ahsg) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361(9360):827-833.
41. Hermans MM, Brandenburg V, Ketteler M, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007;72(2):202-207.
42. Wahl PW, Savage PJ, Psaty BM, et al. Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification. Lancet. 1998;352(9133):1012-1015.
43. Resnick HE, Shorr RI, Kuller L, et al. Prevalence and clinical implications of American Diabetes Association-defined diabetes and other categories of glucose dysregulation in older adults: the health, aging and body composition study. J Clin Epidemiol. 2001;54(9):869-876.
44. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? reanalysis of European epidemiological data: DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ. 1998;317(7155):371-375.
45. Ix JH, Shlipak MG, Sarnak MJ, et al. Fetuin-A is not associated with mortality in chronic kidney disease. Kidney Int. 2007;72(11):1394-1399.
46. Incidence of diabetes in the United States. National Diabetes Information Clearing House. http://diabetes.niddk.nih.gov/dm/pubs/statistics/#11. Accessed May 22, 2007.